Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets

Zeria Pharmaceutical

Status and phase: Completed; Phase 3

Conditions: Primary Hypophosphatemic Rickets

Treatments: Drug: Z-521

Study type: Interventional

Funder types: Industry

Identifiers

NCT01237288

10010301

Details and patient eligibility

About

The purpose of this study is to investigate the efficacy and safety of oral phosphate (Z-521) in subjects with primary hypophosphatemic rickets.

Enrollment: 16 patients

Sex: All

Ages: 1 to 14 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed as primary hypophosphatemic rickets based on familial history, genetic test or laboratory test results.

Exclusion criteria

• A hyperparathyroidism

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

16 participants in 1 patient group

Z-521

Experimental group

Treatment:

Drug: Z-521